BioVendor-Laboratorni medicina a.s. of Brno at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Manufacturers Trader

BioVendor-Laboratorni medicina a.s.

Karasek 1767/1, 621 00 Brno
Czechia

Telephone +420 549124185
Fax +420 549211460
info@biovendor.com

Hall map

MEDICA 2017 hall map (Hall 3): stand K32

Fairground map

MEDICA 2017 fairground map: Hall 3

Contact

Vladimir Kolar

Phone
+420 549 124 197

Email
kolar@biovendor.com

Jan Karasek

Phone
+420 549 124 393

Email
karasek@biovendor.com

Michal Steffl

Phone
+420 549 121 259

Email
trade@testlinecd.com

Imad Faik

Phone
0561 4917420

Email
imad.faik@immunolab.de

Our range of products

Product categories

  • 02  Laboratory Equipment
  • 02.01  Analyser appliances

Analyser appliances

  • 02  Laboratory Equipment
  • 02.01  Analyser appliances
  • 02.01.04  Evaluation units for microtiter plates

Evaluation units for microtiter plates

  • 02  Laboratory Equipment
  • 02.01  Analyser appliances
  • 02.01.15  Fluorometers / fluorometry (Analyser appliances)

Fluorometers / fluorometry (Analyser appliances)

  • 02  Laboratory Equipment
  • 02.01  Analyser appliances
  • 02.01.34  Microplate luminometers

Microplate luminometers

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.02  DNA diagnosis kits

DNA diagnosis kits

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Gene tests / molecular biological diagnostic

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic
  • 03.01.07.02  DNA analysis

DNA analysis

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.01  Allergies

Allergies

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases

Auto-immune diseases

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  • 03.02.03.01  Diagnostics / kits for the diabetes analyses

Diagnostics / kits for the diabetes analyses

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  • 03.02.03.03  Diagnostics / kits for the thyroid gland analyses (Auto-immune diseases)

Diagnostics / kits for the thyroid gland analyses (Auto-immune diseases)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.04  Fertility / Pregnancy hormones / Proteins

Fertility / Pregnancy hormones / Proteins

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.05  Units and systems for hormone determination

Units and systems for hormone determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems

Immuno assay systems

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems
  • 03.02.07.06  Enzyme immunoassay (EIA, ELISA, EMIT)
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems
  • 03.02.07.13  Immunoblots / dotblots

Immunoblots / dotblots

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.09  Individual and specified hormones

Individual and specified hormones

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.09  Individual and specified hormones
  • 03.02.09.01  Diagnostic agents / kits for determination of growth hormones

Diagnostic agents / kits for determination of growth hormones

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.09  Individual and specified hormones
  • 03.02.09.02  Diagnostic agents / kits for determination of Leptin

Diagnostic agents / kits for determination of Leptin

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.12  Rheumatoid diseases

Rheumatoid diseases

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.13  Specific organ function assays

Specific organ function assays

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.14  Specific proteins
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.14  Specific proteins
  • 03.02.14.01  C-reactive proteins (CRP)

C-reactive proteins (CRP)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring

Therapeutic drug monitoring

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  • 03.02.16.01  Diagnostic agents / kits for determination of therapeutic drugs

Diagnostic agents / kits for determination of therapeutic drugs

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers

Tumor markers

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.01  Diagnostic agents / kits for tumour marker determination

Diagnostic agents / kits for tumour marker determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.18  Sepsis markers

Sepsis markers

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology

Bacteriology

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology
  • 03.04.01.03  Bacteriological colony counters

Bacteriological colony counters

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.01  Bacteriology
  • 03.04.01.10  Accessories for Petri dish transport

Accessories for Petri dish transport

  • 03  Diagnostics
  • 03.04  Microbiology
  • 03.04.02  Bacteriology - Identification and susceptibility testing

Bacteriology - Identification and susceptibility testing

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.01  Bacteriology - Infectious immunology

Bacteriology - Infectious immunology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.02  Hepatitis Viruses

Hepatitis Viruses

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.04  Controls / Standards / Calibrators - Infect. immunology

Controls / Standards / Calibrators - Infect. immunology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.05  Equipment and systems for microbiological diagnosis/virology

Equipment and systems for microbiological diagnosis/virology

Our products

Product category: Enzyme immunoassay (EIA, ELISA, EMIT), Tumor markers, Gene tests / molecular biological diagnostic

hsa-miR-21-5p miREIA

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

hsa-miR-21-5p stands out as the most representative miRNA biomarker as it belongs to the first identified miRNA molecules. hsa-miR-21-5p is a circulating miRNA, strongly conserved through evolution, which has been extensively investigated in a range of studies of various diseases, such as cancer, cardiovascular disease, pulmonary diseases, regulation of immunological processes, and many others.

hsa-miR-21-5p was identified as a typical onco-miRNA. It modulates the expression of multiple cancer-related target genes and is dysregulated in various tumors. Besides tissues, recent evidence indicates the presence of miR-21-5p in various types of extracellular fluid, such as plasma, serum, CSF, saliva, gastric juice, pancreatic juice, sputum, and pancreatic cyst fluid. Up-regulated hsa-miR-21-5p could promote tumor growth, metastasis and invasion and reduce sensitivity to chemotherapy. The evidence from published meta-analyses revealed that high expression level of hsa-miR-21-5p was a negative predictor of survival in various cancers.
hsa-miR-21-5p is involved in many types of malignancies including brain cancer, lung cancer, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, esophageal cancer and hepatocellular carcinoma.

Besides altered expression of hsa-miR-21-5p in various malignancies, this miRNA is highly expressed in the cardiovascular system. Recent studies have revealed that its expression in the heart is dysregulated under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure or ischemic heart disease. hsa-miR-21-5p has been found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, calcific aortic valve disease and cardiac fibroblast functions.

More Less

Product category: Enzyme immunoassay (EIA, ELISA, EMIT), Specific proteins

Adipocyte FABP Human ELISA

Adipocyte fatty acid binding protein AFABP is a 15 kDa member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds (bile acids or retinoids) in an internal cavity. AFABP is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells. In mice, targeted mutations in FABP4 (mouse gene is also called aP2 and its relevant protein P2 adipocyte protein or 3T3-L1 lipid binding protein) provide significant protection from hyperinsulinemia and insulin resistance in the context of both dietary and genetic obesity. Adipocytes obtained from AFABP-deficient mice also have reduced efficiency of lipolysis in vitro and in vivo, and these mice exhibited moderately improved systemic dyslipidemia. Recent studies also demonstrated AFABP expression in human macrophages upon differentiation and activation. In these cells, AFABP modulates inflammatory responses and cholesterol ester accumulation, and total or macrophage-specific AFABP deficiency confers dramatic protection against atherosclerosis in the apoE-/- mice. These results indicate a central role for AFABP in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages.

Besides being active within the cell, AFABP appears to be a secreted protein (for normal levels and correlations with certain metabolic parameters see chapter 15). The extracellular role of secreted AFABP remains to be determined.

More Less

Product category: Enzyme immunoassay (EIA, ELISA, EMIT), Specific proteins

PCSK9 Human ELISA

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that plays an important role in the regulation of serum low-density lipoprotein (LDL) cholesterol by downregulation of LDL receptor, and as such is considered a novel target in cholesterol lowering therapy. LDL cholesterol (LDL-C) binds to LDL receptors (LDLRs) on the surface of hepatic cell where the complex is internalized and transported to the endosome. LDL-C dissociates from the receptor and is catabolized whereas the LDLR is recycled to the cell surface for continued clearance of serum cholesterol. PCSK9 affects the receptor recycling pathway by binding to the LDLR and causing degradation of the receptor within the endosome/lysosome compartment. Degradation of the LDLR results in decreased clearance of serum cholesterol, and as a result a higher risk of hypercholesterolemia. Human genetic studies have shown that “gain-of-function” (GOF) mutations in the PCSK9 gene can lead to a form of familial hypercholesterolemia with a higher risk of cardiovascular disease. In contrast, humans with “loss-of-function” (LOF) mutations in the PCSK9 gene have lower serum cholesterol levels and a lower incidence of cardiovascular disease. Thus PCSK9 had a key impact not only on circulating LDL-C level but also on cardiovascular risk and atherosclerotic process.

More Less

Product category: Enzyme immunoassay (EIA, ELISA, EMIT), Specific proteins

Pentraxin 3 Human ELISA

Pentraxin 3 (PTX3, TSG14, Tumor necrosis factor alpha-induced protein 5, Tumor necrosis factor-inducible gene 14 protein) is an evolutionarily conserved, multimeric acute phase inflammatory glycoprotein in the same family as the well-established cardiovascular biomarker C-reactive protein (CRP). It is the prototypical long pentraxin, exhibiting a C-terminal pentraxin domain characteristic of the family, and a unique N-terminal domain [1,13]. PTX3 is mainly produced at extrahepatic sites by several cell types, including cells of the myelomonocyte lineage (monocytes, macrophages, dendritic cells), endothelial cells, smooth muscle cells, fibroblasts, and adipocytes.
PTX3 is also produced during neutrophil differentiation and stored in specific granules of mature neutrophils, ready to be released upon microbial recognition. PTX3 behaves as an acute phase response protein, as the blood levels of PTX3, low in normal conditions (<2 ng/ml in humans), increase rapidly (peaking at 6–8 hours after induction) and dramatically (200–800 ng/ml) during endotoxic shock, sepsis, and other inflammatory and infectious conditions, correlating with the severity of the disease. PTX3 has multiple complex nonredundant functions, ranging from assembly of a hyaluronic acid–rich extracellular matrix and female fertility to protection against pathogens (i.e., Aspergillus fumigatus, influenza viruses). PTX3 also regulates the clearance of apoptotic cells and may participate in maintenance of immunologic tolerance [13]. PTX3 is expressed in response to proinflammatory signals, including bacteria, IL-1 (but not IL-6), and TN-alpha produced primarily by endothelial cells, neutrophils, and macrophages. As a result, inflammation diseases, especially disorders of the immune system such as rheumatoid arthritis, progressive systemic sclerosis, Churg-Straus syndrome, Wegener’s granulomatosis, and microscopic polyangiitis, as well as systemic inflammatory response syndrome (SIRS), result in increased expression of plasma PTX3.
PTX3 is elevated in critically ill patients, with a gradient from systematic inflammatory response syndrome to septic shock, and in several other diseases, such as myocardial infarction, atherosclerosis, small vessel vasculitis and psoriasis. Plasma PTX3 levels have also been suggested to be a good marker for the response to treatment of patients with obstructive sleep apnea (OSA). PTX3 may also be a good diagnostic marker for deterioration in patients with inflammatory bowel disease.
Pentraxin 3 has been proposed as a marker of endothelial dysfunction and inflammation in pre-eclampsia. Pentraxin 3 levels have been found to be elevated in normal pregnancy and also shown to be significantly higher at the time of diagnosis of pre-eclampsia when compared with normal pregnancy. PTX3 may also be elevated in malignancies such as lung carcinoma, prostate cancer and liposarcomas.

More Less

Product category: Gene tests / molecular biological diagnostic

RNA Isolation Kit

Silica-membrane technology
Mini spin columns
Fragment size: ≥ 18 nt
Typical yield: 100 µg small RNA (107 HeLa cells)

More Less

Company news

Date

Topic

Download

Sep 5, 2017

BioVendor New Acquisition - DIAsource ImmunoAssays SA

Communication – press release

Effective 5 September 2017, Biovendor – Laboratorní medicína a.s. (BioVendor) acquired 100% of the shares of DIAsource ImmunoAssays SA from the Australian stock listed company Anteo Diagnostics (ASX: ADO). Anteo Diagnostics had acquired DIAsource in January 2016.

DIAsource ImmunoAssays is a Belgian company specialized since 30 years in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical medical diagnostics. It is based in Louvain-La-Neuve, south of Brussels, and employs 80 people.

DIAsource is a leading provider in IVD market segments such as Vitamin D, ELISA and RIA assays, and produced double digit growth of both revenue and EBITDA over the last five years, for 16.3 Mi € net trade sales income and 3.4 Mi € EBITDA in 2016. It has direct sales representation in Belgium, France and Spain and strong sales in Middle East, Asia, and South America. Its clinical diagnostics product catalog features over 190 ELISA and 140 RIA assays.

For Biovendor, the international company with headquarters in Brno, Czech Republic, this acquisition offers not only an extension with a broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, but also direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries, thereby representing another important step towards internationalization.

With DIAsource representing the largest acquisition to date, BioVendor continues its long-term plan of international expansion after previous acquisitions, in the last three years since 2014, of ImmunoLab (Germany), ViennaLab Diagnostics (Austria), and Oxford Biosystems (UK), following to previous acquisition of TestLine Clinical Diagnostics (Czech Republic).

DIAsource ImmunoAssays, www.diasource-diagnostics.com

based in Louvain-La-Neuve, Belgium, manufactures and sells manual kits and open automation for clinical diagnostics in more than 70 countries worldwide, both direct and via its worldwide network of distribution partners.

BioVendor group, www.biovendor.com/biovendor-group

an international diagnostics holding with headquarters in Brno, Czech Republic, employs over 380 employees across 14 companies operating in six countries. 

BioVendor is 60% controlled by Consillium, the investment company of Mr. Tomáš Němec, and 40% owned by Dr. Viktor Růžička, its founder and Chairman.

More Less

Sep 1, 2017

Launch of the first miREIA kit

We are proud to announce launch of the first miREIA kit. The hsa-miR-21-5p miREIA kit allows quantitative determination of the most frequently studied human miRNA-21-5p in blood samples. Next miREIA kits are coming very soon.

More Less

About us

Company details

BioVendor group is an internationally operating group of companies with its own research & development and manufacturing capability.

In 2012, BioVendor – Laboratorní medicína joined forces with Test Line Clinical Diagnostics followed by BioVendor Instruments, Immunolab, ViennaLab Diagnostics and Genetrac by the end of 2016. We have established a synergistic and quality-based portfolio which allows us to serve professionals from the fields of biomedical research, clinical diagnostics, veterinary diagnostics and food analysis.

The BioVendor group has over 380 employees among its 14 companies operating in 6 countries, 5 R&D facilities, 4 industry sites, and 4 sales companies or branches. We collaborate with more than 60 distributors creating a complete end-to-end workflow with enhanced customer service and technical support.

More Less

Company data

Sales volume

10-49 Mio US $

Number of employees

500-999

Area of business
  • Electromedical equipment / Medical Technology
  • Laboratory Equipment
  • Diagnostics